Concepts (226)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Squamous Cell | 6 | 2020 | 1097 | 0.880 |
Why?
|
Head and Neck Neoplasms | 5 | 2020 | 1060 | 0.800 |
Why?
|
Triple Negative Breast Neoplasms | 1 | 2022 | 163 | 0.690 |
Why?
|
Chemoradiotherapy | 2 | 2020 | 309 | 0.600 |
Why?
|
Cisplatin | 1 | 2020 | 598 | 0.590 |
Why?
|
Tertiary Care Centers | 1 | 2014 | 110 | 0.430 |
Why?
|
Skin Ulcer | 1 | 2012 | 25 | 0.420 |
Why?
|
Hodgkin Disease | 1 | 2012 | 181 | 0.380 |
Why?
|
Adenosine Deaminase | 1 | 2011 | 21 | 0.370 |
Why?
|
Uric Acid | 1 | 2011 | 136 | 0.360 |
Why?
|
C-Reactive Protein | 1 | 2011 | 191 | 0.340 |
Why?
|
Registries | 1 | 2014 | 791 | 0.330 |
Why?
|
Skin | 1 | 2012 | 589 | 0.320 |
Why?
|
Mouth Neoplasms | 3 | 2020 | 198 | 0.320 |
Why?
|
Lymph Nodes | 1 | 2012 | 552 | 0.320 |
Why?
|
Naegleria fowleri | 1 | 2008 | 1 | 0.310 |
Why?
|
Central Nervous System Protozoal Infections | 1 | 2008 | 1 | 0.310 |
Why?
|
Amebiasis | 1 | 2008 | 3 | 0.310 |
Why?
|
Mouth Mucosa | 2 | 2015 | 68 | 0.310 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 4 | 2013 | 2503 | 0.240 |
Why?
|
India | 6 | 2020 | 125 | 0.240 |
Why?
|
Leiomyosarcoma | 2 | 2015 | 45 | 0.220 |
Why?
|
Granuloma, Giant Cell | 1 | 2003 | 5 | 0.220 |
Why?
|
Pharyngeal Diseases | 1 | 2003 | 11 | 0.220 |
Why?
|
Bone Diseases | 1 | 2003 | 57 | 0.210 |
Why?
|
Sigmoid Neoplasms | 1 | 2002 | 9 | 0.210 |
Why?
|
Humans | 36 | 2023 | 89613 | 0.210 |
Why?
|
Adult | 16 | 2020 | 26704 | 0.200 |
Why?
|
Adenocarcinoma, Mucinous | 1 | 2002 | 48 | 0.200 |
Why?
|
Teratoma | 4 | 2010 | 52 | 0.200 |
Why?
|
Carcinoma | 2 | 2023 | 438 | 0.200 |
Why?
|
Tomography, X-Ray Computed | 8 | 2012 | 2668 | 0.190 |
Why?
|
Penile Neoplasms | 2 | 2015 | 17 | 0.190 |
Why?
|
Neoplasm Staging | 3 | 2020 | 2003 | 0.190 |
Why?
|
Aged | 13 | 2020 | 19158 | 0.190 |
Why?
|
Male | 22 | 2023 | 42488 | 0.190 |
Why?
|
Female | 22 | 2023 | 46401 | 0.190 |
Why?
|
Sclerotherapy | 1 | 2001 | 16 | 0.190 |
Why?
|
Esophageal and Gastric Varices | 1 | 2001 | 35 | 0.190 |
Why?
|
Abnormalities, Radiation-Induced | 1 | 2001 | 2 | 0.190 |
Why?
|
Programmed Cell Death 1 Receptor | 1 | 2022 | 173 | 0.190 |
Why?
|
Esophageal Diseases | 1 | 2001 | 27 | 0.190 |
Why?
|
Middle Aged | 16 | 2023 | 26012 | 0.180 |
Why?
|
Esophagus | 1 | 2001 | 107 | 0.180 |
Why?
|
Pancreatectomy | 1 | 2001 | 164 | 0.180 |
Why?
|
Combined Modality Therapy | 5 | 2020 | 1705 | 0.180 |
Why?
|
Neoplasms | 2 | 2014 | 3054 | 0.180 |
Why?
|
Attitude to Health | 1 | 2001 | 222 | 0.170 |
Why?
|
Placenta | 1 | 2001 | 181 | 0.160 |
Why?
|
Neoadjuvant Therapy | 1 | 2022 | 375 | 0.160 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2020 | 538 | 0.160 |
Why?
|
Ethanol | 1 | 2001 | 252 | 0.160 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2001 | 237 | 0.150 |
Why?
|
Prospective Studies | 5 | 2023 | 4309 | 0.150 |
Why?
|
Anti-Inflammatory Agents | 1 | 2001 | 345 | 0.150 |
Why?
|
Survival Rate | 3 | 2020 | 1887 | 0.150 |
Why?
|
Patient Safety | 1 | 2020 | 218 | 0.140 |
Why?
|
Young Adult | 4 | 2014 | 6368 | 0.140 |
Why?
|
Disease-Free Survival | 1 | 2020 | 1172 | 0.140 |
Why?
|
Follow-Up Studies | 5 | 2014 | 3659 | 0.140 |
Why?
|
Penis | 2 | 2015 | 61 | 0.140 |
Why?
|
Socioeconomic Factors | 2 | 2014 | 592 | 0.130 |
Why?
|
Hoarseness | 1 | 2015 | 11 | 0.130 |
Why?
|
Vocal Cords | 1 | 2015 | 28 | 0.130 |
Why?
|
Pancreatic Neoplasms | 1 | 2001 | 682 | 0.130 |
Why?
|
Child | 7 | 2014 | 7216 | 0.120 |
Why?
|
Laryngeal Neoplasms | 1 | 2015 | 89 | 0.120 |
Why?
|
Doxorubicin | 2 | 2013 | 294 | 0.120 |
Why?
|
Prognosis | 4 | 2023 | 3785 | 0.120 |
Why?
|
Positron-Emission Tomography | 2 | 2013 | 337 | 0.110 |
Why?
|
Eosinophilic Granuloma | 1 | 2013 | 11 | 0.110 |
Why?
|
Family Characteristics | 1 | 2014 | 49 | 0.110 |
Why?
|
Colitis, Ulcerative | 1 | 2001 | 749 | 0.110 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 3 | 2005 | 185 | 0.110 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2023 | 1125 | 0.110 |
Why?
|
Adolescent | 7 | 2014 | 9305 | 0.110 |
Why?
|
Demography | 1 | 2014 | 183 | 0.110 |
Why?
|
Vagus Nerve Diseases | 1 | 2012 | 1 | 0.110 |
Why?
|
Cranial Nerve Neoplasms | 1 | 2012 | 12 | 0.110 |
Why?
|
Vinblastine | 1 | 2012 | 100 | 0.100 |
Why?
|
Neurilemmoma | 1 | 2012 | 34 | 0.100 |
Why?
|
Bleomycin | 1 | 2012 | 103 | 0.100 |
Why?
|
Mouth Diseases | 1 | 2012 | 16 | 0.100 |
Why?
|
Dacarbazine | 1 | 2012 | 101 | 0.100 |
Why?
|
Opportunistic Infections | 1 | 2012 | 60 | 0.100 |
Why?
|
Treatment Outcome | 5 | 2020 | 8218 | 0.100 |
Why?
|
Melanoma | 1 | 2015 | 468 | 0.090 |
Why?
|
Plants, Medicinal | 1 | 2011 | 42 | 0.090 |
Why?
|
Ondansetron | 1 | 2010 | 21 | 0.090 |
Why?
|
Mycoses | 1 | 2011 | 46 | 0.090 |
Why?
|
Serotonin Antagonists | 1 | 2010 | 35 | 0.090 |
Why?
|
Quinuclidines | 1 | 2010 | 26 | 0.090 |
Why?
|
Antineoplastic Agents | 2 | 2020 | 2327 | 0.090 |
Why?
|
Isoquinolines | 1 | 2010 | 73 | 0.090 |
Why?
|
Anti-Infective Agents | 1 | 2011 | 91 | 0.090 |
Why?
|
Lung Neoplasms | 1 | 2023 | 2364 | 0.090 |
Why?
|
Drug Therapy, Combination | 2 | 2010 | 782 | 0.090 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2013 | 297 | 0.080 |
Why?
|
Retroperitoneal Neoplasms | 1 | 2010 | 44 | 0.080 |
Why?
|
Bacterial Infections | 1 | 2011 | 184 | 0.080 |
Why?
|
Antiemetics | 1 | 2010 | 98 | 0.080 |
Why?
|
Nausea | 1 | 2010 | 175 | 0.080 |
Why?
|
Plant Extracts | 1 | 2011 | 245 | 0.080 |
Why?
|
Biopsy | 1 | 2012 | 1183 | 0.080 |
Why?
|
Dexamethasone | 1 | 2010 | 343 | 0.080 |
Why?
|
Ceftazidime | 1 | 2008 | 8 | 0.080 |
Why?
|
Amphotericin B | 1 | 2008 | 34 | 0.080 |
Why?
|
Cerebrospinal Fluid | 1 | 2008 | 31 | 0.080 |
Why?
|
Rifampin | 1 | 2008 | 23 | 0.080 |
Why?
|
Treatment Refusal | 1 | 2008 | 62 | 0.080 |
Why?
|
Empyema | 1 | 2007 | 9 | 0.070 |
Why?
|
Chin | 1 | 2007 | 8 | 0.070 |
Why?
|
Fatal Outcome | 1 | 2008 | 296 | 0.070 |
Why?
|
Cleft Lip | 1 | 2007 | 15 | 0.070 |
Why?
|
Aged, 80 and over | 3 | 2014 | 6771 | 0.070 |
Why?
|
Abscess | 1 | 2007 | 94 | 0.070 |
Why?
|
Neutrophils | 2 | 2023 | 311 | 0.070 |
Why?
|
Radiotherapy Dosage | 4 | 2012 | 469 | 0.070 |
Why?
|
Brain Neoplasms | 1 | 1990 | 785 | 0.060 |
Why?
|
Radiation Injuries | 1 | 2005 | 162 | 0.060 |
Why?
|
Sex Distribution | 2 | 2001 | 171 | 0.060 |
Why?
|
Risk Assessment | 2 | 2001 | 2304 | 0.050 |
Why?
|
Angiogenesis Inducing Agents | 1 | 2003 | 30 | 0.050 |
Why?
|
Skull Base | 1 | 2003 | 48 | 0.050 |
Why?
|
Surveys and Questionnaires | 2 | 2020 | 2646 | 0.050 |
Why?
|
Radiation Dosage | 2 | 2000 | 226 | 0.050 |
Why?
|
Androgen Antagonists | 1 | 2003 | 138 | 0.050 |
Why?
|
Laparotomy | 1 | 2001 | 68 | 0.050 |
Why?
|
Sclerosing Solutions | 1 | 2001 | 5 | 0.050 |
Why?
|
Tissue Extracts | 1 | 2001 | 24 | 0.050 |
Why?
|
Biopsy, Needle | 1 | 2001 | 231 | 0.050 |
Why?
|
Mucous Membrane | 1 | 2001 | 83 | 0.050 |
Why?
|
Colorectal Neoplasms | 1 | 2009 | 979 | 0.050 |
Why?
|
Prostate-Specific Antigen | 1 | 2003 | 337 | 0.050 |
Why?
|
Lymphocytes | 1 | 2023 | 468 | 0.050 |
Why?
|
Esophagoscopy | 1 | 2001 | 90 | 0.050 |
Why?
|
Age Distribution | 1 | 2001 | 199 | 0.040 |
Why?
|
Tobacco Use | 1 | 2020 | 27 | 0.040 |
Why?
|
Breast Neoplasms | 2 | 2007 | 3021 | 0.040 |
Why?
|
Health Surveys | 1 | 2001 | 240 | 0.040 |
Why?
|
Incidence | 2 | 2001 | 1598 | 0.040 |
Why?
|
Patient Participation | 1 | 2001 | 226 | 0.040 |
Why?
|
Dengue | 1 | 1998 | 44 | 0.040 |
Why?
|
Disease Outbreaks | 1 | 1998 | 156 | 0.040 |
Why?
|
Tongue Neoplasms | 1 | 1997 | 52 | 0.040 |
Why?
|
Lung | 1 | 2023 | 1273 | 0.030 |
Why?
|
Glottis | 1 | 2015 | 10 | 0.030 |
Why?
|
Sphenoid Bone | 1 | 1995 | 9 | 0.030 |
Why?
|
Ependymoma | 1 | 1995 | 18 | 0.030 |
Why?
|
Larynx | 1 | 2015 | 37 | 0.030 |
Why?
|
Spinal Cord Neoplasms | 1 | 1995 | 48 | 0.030 |
Why?
|
Meningioma | 1 | 1995 | 62 | 0.030 |
Why?
|
Meningeal Neoplasms | 1 | 1995 | 66 | 0.030 |
Why?
|
Neoplasms, Multiple Primary | 1 | 1995 | 103 | 0.030 |
Why?
|
Retrospective Studies | 3 | 2023 | 9127 | 0.030 |
Why?
|
Radiography, Panoramic | 1 | 2013 | 7 | 0.030 |
Why?
|
Gingiva | 1 | 2013 | 8 | 0.030 |
Why?
|
Prednisolone | 1 | 2013 | 40 | 0.030 |
Why?
|
Vincristine | 1 | 2013 | 111 | 0.030 |
Why?
|
Cyclophosphamide | 1 | 2013 | 301 | 0.030 |
Why?
|
Proteus Infections | 1 | 2012 | 1 | 0.030 |
Why?
|
Candidiasis, Oral | 1 | 2012 | 4 | 0.030 |
Why?
|
Staphylococcus epidermidis | 1 | 2012 | 15 | 0.030 |
Why?
|
Fungemia | 1 | 2012 | 15 | 0.030 |
Why?
|
Escherichia coli Infections | 1 | 2012 | 35 | 0.030 |
Why?
|
Klebsiella Infections | 1 | 2012 | 30 | 0.030 |
Why?
|
Aspergillosis | 1 | 2012 | 41 | 0.030 |
Why?
|
Leukocyte Count | 1 | 2012 | 223 | 0.030 |
Why?
|
Pseudomonas Infections | 1 | 2012 | 99 | 0.020 |
Why?
|
Prostatic Neoplasms | 1 | 2003 | 1734 | 0.020 |
Why?
|
Bacteremia | 1 | 2012 | 102 | 0.020 |
Why?
|
Fungi | 1 | 2011 | 66 | 0.020 |
Why?
|
Microbial Sensitivity Tests | 1 | 2011 | 150 | 0.020 |
Why?
|
Radiation Protection | 1 | 1990 | 26 | 0.020 |
Why?
|
Recurrence | 1 | 2013 | 1143 | 0.020 |
Why?
|
Skin Neoplasms | 1 | 2015 | 589 | 0.020 |
Why?
|
alpha-Fetoproteins | 1 | 2010 | 44 | 0.020 |
Why?
|
Cross-Over Studies | 1 | 2010 | 387 | 0.020 |
Why?
|
Radiography, Abdominal | 1 | 2010 | 69 | 0.020 |
Why?
|
Staphylococcal Infections | 1 | 2012 | 271 | 0.020 |
Why?
|
Nigeria | 1 | 2010 | 157 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2013 | 1605 | 0.020 |
Why?
|
Infant | 2 | 2010 | 3176 | 0.020 |
Why?
|
Vomiting | 1 | 2010 | 195 | 0.020 |
Why?
|
Child, Preschool | 2 | 2010 | 3756 | 0.020 |
Why?
|
Acute Disease | 1 | 2010 | 842 | 0.020 |
Why?
|
Animals | 1 | 2008 | 27481 | 0.020 |
Why?
|
Biomarkers, Tumor | 2 | 2010 | 1541 | 0.020 |
Why?
|
Infant, Newborn | 2 | 2007 | 2488 | 0.020 |
Why?
|
Rectum | 1 | 2009 | 148 | 0.020 |
Why?
|
Bacteria | 1 | 2011 | 481 | 0.020 |
Why?
|
Palliative Care | 1 | 2009 | 264 | 0.020 |
Why?
|
Cohort Studies | 1 | 2012 | 2878 | 0.020 |
Why?
|
Colon | 1 | 2009 | 519 | 0.020 |
Why?
|
Fluoroscopy | 1 | 2005 | 123 | 0.020 |
Why?
|
Respiratory Insufficiency | 1 | 2007 | 161 | 0.020 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 1985 | 48 | 0.020 |
Why?
|
Ultrasonography | 1 | 2007 | 714 | 0.010 |
Why?
|
Testicular Neoplasms | 1 | 1985 | 113 | 0.010 |
Why?
|
Mammography | 1 | 2007 | 474 | 0.010 |
Why?
|
Platelet Factor 4 | 1 | 2003 | 12 | 0.010 |
Why?
|
Comorbidity | 1 | 2007 | 952 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 1995 | 3465 | 0.010 |
Why?
|
Vascular Endothelial Growth Factors | 1 | 2003 | 56 | 0.010 |
Why?
|
Endothelial Growth Factors | 1 | 2003 | 55 | 0.010 |
Why?
|
Lymphokines | 1 | 2003 | 75 | 0.010 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 2003 | 57 | 0.010 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2003 | 182 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 373 | 0.010 |
Why?
|
Protein Isoforms | 1 | 2003 | 276 | 0.010 |
Why?
|
Risk Factors | 1 | 2012 | 5517 | 0.010 |
Why?
|
Time Factors | 1 | 2010 | 5337 | 0.010 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2003 | 405 | 0.010 |
Why?
|
Computer Simulation | 1 | 2005 | 1101 | 0.010 |
Why?
|
Angiogenesis Inhibitors | 1 | 2003 | 293 | 0.010 |
Why?
|
Pilot Projects | 1 | 2003 | 870 | 0.010 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2000 | 188 | 0.010 |
Why?
|
Age of Onset | 1 | 2001 | 314 | 0.010 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2000 | 294 | 0.010 |
Why?
|
Climate | 1 | 1998 | 58 | 0.010 |
Why?
|
Mastectomy | 1 | 2000 | 246 | 0.010 |
Why?
|
Parotid Gland | 1 | 1997 | 32 | 0.010 |
Why?
|
Evaluation Studies as Topic | 1 | 1997 | 270 | 0.010 |
Why?
|
Antibodies, Viral | 1 | 1998 | 311 | 0.010 |
Why?
|
Spinal Cord | 1 | 1995 | 255 | 0.010 |
Why?
|
Dysgerminoma | 1 | 1985 | 7 | 0.000 |
Why?
|